Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $13.27 USD
Change Today +0.12 / 0.91%
Volume 212.2K
JNP On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

juniper pharmaceuticals inc (JNP) Snapshot

Open
$14.00
Previous Close
$13.15
Day High
$14.00
Day Low
$13.02
52 Week High
09/4/15 - $14.00
52 Week Low
01/12/15 - $5.09
Market Cap
143.2M
Average Volume 10 Days
83.7K
EPS TTM
$0.22
Shares Outstanding
10.8M
EX-Date
--
P/E TM
61.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for JUNIPER PHARMACEUTICALS INC (JNP)

Related News

No related news articles were found.

juniper pharmaceuticals inc (JNP) Related Businessweek News

No Related Businessweek News Found

juniper pharmaceuticals inc (JNP) Details

Juniper Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing therapeutics that address unmet medical needs in women's health. The company develops its products using its drug delivery technologies, including bioadhesive delivery system and a segmented intra-vaginal ring technology. It develops and markets five bioadhesive gel products, including CRINONE, a progesterone gel for use in infertility, which is marketed by Actavis, Inc. in the United States and by Merck Serono S.A. in approximately 60 countries worldwide. The company is also developing COL-1077, a 10% lidocaine bioadhesive gel intended as an acute use anesthetic for minimally invasive gynecological procedures. In addition, it provides pharmaceutical development, clinical trial supply manufacturing, and analytical services, as well as consultative services to its pharmaceutical industry customers. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.

85 Employees
Last Reported Date: 03/18/15
Founded in 1986

juniper pharmaceuticals inc (JNP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $340.0K
Chief Financial Officer, Vice President, Trea...
Total Annual Compensation: $75.0K
Chief Operating Officer and Director
Total Annual Compensation: $284.6K
Compensation as of Fiscal Year 2014.

juniper pharmaceuticals inc (JNP) Key Developments

Juniper Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Juniper Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company’s total revenue was $10,213,000 against $6,654,000 a year ago. Loss from operations was $333,000 against income from operations of $79,000 a year ago. Loss before taxes was $323,000 against income before tax of $156,000 last year. Net loss was $326,000 or $0.03 per diluted share against $10,000 or $0.01 per diluted share a year ago. Adjusted EBITDA was $583,000 against $798,000 a year ago. Total revenues increased 53% year-over-year to $10.2 million, driven by an 89% increase in product revenues and 29% growth in service revenues. For the six months, the company’s total revenue was $11,510,000 against $6,802,000 a year ago. Loss from operations was $1,164,000 against $29,000 a year ago. Loss before taxes was $1,010,000 against income before income taxes of $320,000 a year ago. Net loss was $1,018,000 or $0.09 per diluted share against net income of $142,000 or $0.02 per diluted share a year ago. Adjusted EBITDA was $978,000 against $1,300,000 a year ago.

Juniper Pharmaceuticals Announces Regulatory Approvals for CRINONE® Progesterone Gel in Nine New EU Countries

Juniper Pharmaceuticals, Inc. announced that the regulatory bodies of nine new European Union (EU) countries, including Poland and France, have granted marketing authorization to CRINONE® (progesterone gel) under the mutual-recognition procedure (MRP). These approvals further expand the global CRINONE® franchise, giving women in these nine countries a new, patient-friendly therapeutic option for their progesterone replacement or supplementation needs. The recently-approved countries are: Bulgaria, Estonia, France, Iceland, Latvia, Lithuania, the Netherlands, Poland, and Romania. The reference member state for this MRP is Germany.

Juniper Pharmaceuticals, Inc. Announces Board Changes

On July 16, 2015, the Board of Directors of Juniper Pharmaceuticals, Inc. appointed Ann Merrifield as a new director of the company, upon the recommendation of its Nominating & Governance Committee. Ms. Merrifield will serve until the company's 2016 annual meeting of stockholders. Ms. Merrifield will also serve as a member of the company's Compensation Committee and its Nominating and Corporate Governance Committee. Ms. Merrifield was previously the President and Chief Executive Officer of PathoGenetix, Inc., from December 2012 to July 2014. As previously disclosed, at the 2015 Annual Meeting of Stockholders of the company, held on July 7, 2015, Donald Hunter received fewer votes for election to Board of Directors than votes against election. As a result, Mr. Hunter offered to resign from the Board in accordance with amended and restated bylaws. On July 16, 2015, the Board considered Mr. Hunter's qualifications as a director and as Chairman of the Audit Committee and decided to undertake a search for a qualified successor to fill Mr. Hunter's seat on the Board. The Board accepted Mr. Hunter's resignation, to be effective upon the appointment of a qualified successor.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNP:US $13.27 USD +0.12

JNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $43.07 USD -1.07
View Industry Companies
 

Industry Analysis

JNP

Industry Average

Valuation JNP Industry Range
Price/Earnings 62.9x
Price/Sales 3.8x
Price/Book 3.5x
Price/Cash Flow 63.6x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JUNIPER PHARMACEUTICALS INC, please visit www.juniperpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.